Sangamo Therapeutics Inc.
- Address
- 501 Canal Boulevard Suite A100
Sponsor Overview
Specializations
Fabry disease and lysosomal storage disorders
Research activity is centered on Fabry disease, with attention to alpha-galactosidase A replacement through gene therapy approaches and long-term clinical follow-up in affected subjects.
- Fabry disease
- Alpha-galactosidase A gene therapy
- Long-term safety and tolerability
The sponsor’s clinical work in this area includes ongoing interest in durable treatment effects and extended safety monitoring for inherited metabolic disease.
Kidney transplant rejection and transplant immunology
Clinical research also includes kidney transplant rejection, reflecting involvement in transplant immunology and immune-mediated complications affecting graft survival.
- Kidney transplant rejection
- Graft immune response
- Transplant-related safety
This area indicates therapeutic interest in conditions where immune control and organ preservation are central clinical concerns.
Gene therapy and genetic medicine
The sponsor’s portfolio includes gene therapy programs built around treatment of inherited disease, with emphasis on AAV-based delivery platforms and correction of underlying genetic deficiency.
- Gene therapy
- AAV-based vectors
- Inherited metabolic disease
These activities place genetic intervention at the center of its therapeutic research interests.
Long-term follow-up and treatment durability
Several studies focus on extended observation after treatment, with attention to long-term follow-up, persistent safety, and ongoing tolerability in chronic genetic disease settings.
- Long-term follow-up
- Durability of response
- Chronic safety monitoring
This reflects a clinical interest in sustained therapeutic benefit and continued patient monitoring over time.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Long-Term Follow-Up Study of TX200-TR101 in Patients with Kidney Transplant Rejection |  Belgium The Netherlands | Not Recruiting |
| Long-Term Safety Evaluation of Isaralgagene Civaparvovec Gene Therapy in Patients with Fabry Disease |  Germany | Not Recruiting |
| Safety and Tolerability Assessment of Isaralgagene Civaparvovec Gene Therapy in Fabry Disease: A Phase I/II, Multicenter, Open-Label, Dose-Ranging Study | Germany Italy | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials165 other sponsors
- 2.Immune system processes1 trial65 other sponsors
Partnered Research Centres
7 centres- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Dr. Molewaterplein 40, 3015 GD Rotterdam
- Address
- Herestraat 49, 3000 Leuven
- Address
- Straubmuehlweg 2a, Grombuehl, 97078 Würzburg
- Address
- Hanzeplein 1, 9713 GZ Groningen
- Address
- Rapenburg 70, 2311 EZ Leiden
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Sangamo Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.